Business Description
Aktis Oncology Inc
NAICS : 541715
SIC : 2834
ISIN : US01021M1045
Total Employee Number:
79Description
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 46.51 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.3 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 12.38 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -35.5 | |||||
3-Year EPS without NRI Growth Rate | -32.6 | |||||
3-Year FCF Growth Rate | -33.8 | |||||
3-Year Book Growth Rate | -96.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 61.55 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.88 | |||||
9-Day RSI | 41.7 | |||||
14-Day RSI | 47.97 | |||||
3-1 Month Momentum % | 22.93 | |||||
6-1 Month Momentum % | 5.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 19.49 | |||||
Quick Ratio | 19.49 | |||||
Cash Ratio | 19.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -23.99 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -786.37 | |||||
Net Margin % | -656.52 | |||||
EBITDA Margin % | -759.94 | |||||
FCF Margin % | -511.99 | |||||
OCF Margin % | -475.61 | |||||
ROE % | -44.11 | |||||
ROA % | -8.96 | |||||
ROIC % | -73.55 | |||||
3-Year ROIIC % | -107.21 | |||||
ROC (Joel Greenblatt) % | -150.95 | |||||
ROCE % | -11.62 | |||||
Moat Score | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 246.8 | |||||
PB Ratio | 2.75 | |||||
Price-to-Tangible-Book | 2.75 | |||||
EV-to-EBIT | -21.57 | |||||
EV-to-EBITDA | -22.32 | |||||
EV-to-Revenue | 169.65 | |||||
EV-to-Forward-Revenue | 82.67 | |||||
EV-to-FCF | -33.14 | |||||
| Price-to-Net-Current-Asset-Value | 2.94 | |||||
| Price-to-Net-Cash | 2.98 | |||||
Earnings Yield (Greenblatt) % | -4.64 | |||||
FCF Yield % | -1.88 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AKTS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aktis Oncology Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5.097 | ||
| EPS (TTM) ($) | -0.668 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 47.97 | ||
| 14-Day ATR ($) | 2.532905 | ||
| 20-Day SMA ($) | 27.345 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 14.72 - 34.1899 | ||
| Shares Outstanding (Mil) | 55.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aktis Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aktis Oncology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-30 | In 138 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | In 47 days | ||
| General meeting for 2025 | 2026-07-16 | In 1 day | ||
| Jefferies Global Healthcare Conference | 2026-06-03 16:20 | 20.26 (+5.08%) | ||
| Aktis Oncology: AKY-2519 Clinical Imaging and Dosimetry Data Conference Call | 2026-05-27 08:00 | 20.58 (-0.77%) | ||
| BofA Securities Health Care Conference | 2026-05-13 10:00 | 19.73 (+7.70%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 18.60 (-1.06%) | ||
| Clinical development strategy for AKY-2519 | 2026-05-05 08:00 | 19.00 (-1.35%) | ||
| Annual report for 2025 | 2026-03-30 | 15.19 (-12.04%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 15.19 (-12.04%) |
Show
Entries
Aktis Oncology Inc Frequently Asked Questions
What is Aktis Oncology Inc(AKTS)'s stock price today?
The current price of AKTS is $25.18. The 52 week high of AKTS is $34.19 and 52 week low is $14.72.
When is next earnings date of Aktis Oncology Inc(AKTS)?
The next earnings date of Aktis Oncology Inc(AKTS) is 2026-08-31 Est..
Does Aktis Oncology Inc(AKTS) pay dividends? If so, how much?
Aktis Oncology Inc(AKTS) does not pay dividend.
Guru Commentaries on NAS:AKTS
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Aktis Oncology Inc
No articles.
Headlines
See More- 1
Jun 16, 2026
Aktis is a Strong Buy at Raymond James on therapeutic platform
Seeking Alpha • 11:28am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers